Download Certificate- CMOs | ECIO | Most Admired Brand | Most Trusted Company

Phase 1 trial of COVID-19 antibody drug begins


By MYBRANDBOOK


Phase 1 trial of COVID-19 antibody drug begins

US Pharma company Eli Lilly has started dosing participants in the Phase I clinical trial of antibody therapy to treat coronavirus. This is said to be the world’s first study to assess an antibody treatment for the disease.

 

Lilly is one of the several drugmakers and research institutions that are working on vaccines, antivirals and other treatments to help those infected with the fast-spreading novel coronavirus, which has already killed over 370,000 worldwide.

 

Lilly developed the antibody in three months after AbCellera and the National Institute of Allergy and Infectious Diseases (NIAID)’s Vaccine Research Center discovered it from a blood sample of one of the first patients who recovered from Covid-19 in the US.

 

An antiviral drug from Gilead Sciences called Remdesivir has shown some promise against COVID-19 and is being given to patients by some countries under compassionate or emergency use rule.

 

Lilly said its early stage study will assess safety and tolerability in patients hospitalized with COVID-19 and results are anticipated by the end of June.

 

The experimental treatment, LY-CoV555, has been developed through collaboration with privately held AbCellera Biologics, which Lilly partnered with in March.

 

Lilly’s treatment is an antibody directed against the spike-shaped protein structures of the virus and is designed to block it from locking on to human cells, thus neutralizing the virus.

 

The drugmaker said the antibody treatment was developed after it was identified from a blood sample taken from one of the first U.S. patients who recovered from the lung illness caused by the new coronavirus.

 

“Antibody therapies such as LY-CoV555 may have potential for both prevention and treatment of Covid-19 and may be particularly important for groups hardest hit by the disease such as the elderly and those with compromised immune systems.”

 

If the antibody treatment is found to be safe in Phase I trial, Lilly will assess it in non-hospitalised Covid-19 patients and in a preventative setting.

 E-Magazine 
 VIDEOS  Placeholder image

Copyright www.mybrandbook.co.in @1999-2024 - All rights reserved.
Reproduction in whole or in part in any form or medium without express written permission of Kalinga Digital Media Pvt. Ltd. is prohibited.
Other Initiatives : www.varindia.com | www.spoindia.org